Pricing Log in Create free account

Polyrizon Ltd. (PLRZ) vs TransCode Therapeutics Inc. (RNAZ)

Polyrizon Ltd. and TransCode Therapeutics Inc. are both Biotechnology companies. Polyrizon Ltd. and TransCode Therapeutics Inc. are of similar size ($27.5M and $25.6M). Across the 6 metrics below, Polyrizon Ltd. leads on 4 and TransCode Therapeutics Inc. on 2.

Valuation

Metric PLRZ RNAZ Biotechnology median
P/E — n/m 10.60
P/S — n/m 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.11 0.66
EV/Sales n/m n/m 9.02
Earnings yield — (3,354.19%) (32.88%)
Free cash flow yield 0.00% (1,565.69%) (23.13%)

Profitability

Metric PLRZ RNAZ Biotechnology median
Gross margin — 0.00% 68.51%
Operating margin — 0.00% 0.00%
Net margin — 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 429.61% (51.96%)
Return on assets 0.00% (58.12%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PLRZ RNAZ Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 99.39% 96.02% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric PLRZ RNAZ Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 36.37 1.97 4.97
Net debt to EBITDA 2.11 0.64 1.01

Dividend

Metric PLRZ RNAZ Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PLRZ RNAZ Biotechnology median
Market cap 27.49m 25.57m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack